Longitudinal investigation of quantitative MR imaging marker in leg muscles in Morbus Pompe

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00023874

Enrollment

Registered

2021-01-08

Start date

2021-01-11

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E74.0

Interventions

Group 1: Pompe Patients All participants will be undergo the same study protocol six times at intervals of 3-4 months. An examination day will include written inform content, questionnaires to obtain

Eligibility

Sex/Gender

All

Age

16 Years to 100 Years

Inclusion criteria

Inclusion criteria: Ensured diagnosis of Morbus Pompe OR no neuromuscular disorders at all (healthy controls)

Exclusion criteria

Exclusion criteria: MR contraindications e.g. implants, respiratory insufficency

Design outcomes

Primary

Measure	Time frame
i)After finishing acquisition and evaluation of all participants for timepoint 1, we will perform initial cross sectional comparisons between LOPD patients and matched controls to reproduce our previous findings, of increased diffusivity in LOPD muscles with <10% fat. ii)After finishing all acquisitions longitudinal analysis of quantitative parameters (diffusion, fat and T2) in LOPD patients and in controls, and the analysis of the interaction between the timespan and the population group will be performed	—

Measure

Time frame

i)After finishing acquisition and evaluation of all participants for timepoint 1, we will perform initial cross sectional comparisons between LOPD patients and matched controls to reproduce our previous findings, of increased diffusivity in LOPD muscles with <10% fat. ii)After finishing all acquisitions longitudinal analysis of quantitative parameters (diffusion, fat and T2) in LOPD patients and in controls, and the analysis of the interaction between the timespan and the population group will be performed

—

Countries

Germany

Contacts

Public ContactLara Schlaffke

BG UK Bergmannsheil / Neurologie

lara.schlaffke@rub.de+49 234 3026098

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026